Akili Interactive, a digital therapeutics company developing a video game-based product (AKL-T01) designed to improve cognitive impairment, came to VeraSci for assistance in executing a randomized, controlled clinical trial in pediatric patients with ADHD.  AKL-T01 (EndeavorRx) is a novel digital therapeutic that targets attention control through a video game-based interface.

Download this case study to learn how VeraSci’s efforts contributed to the success of the STARS-ADHD trial and, ultimately, to clearance by the FDA.


Click Here to Visit the Full VeraSci Site